Epigenetics of neurodegenerative diseases

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

Epigenetics and Neurodegenerative Diseases: A Short, Easy-to-Understand Guide

What is epigenetics?
Epigenetics studies how gene activity is turned on or off without changing the DNA sequence. In the brain, small chemical marks on DNA, on histone proteins, and on non-coding RNAs help control which genes are active. Changes in these marks can influence neuron health and may contribute to neurodegenerative diseases.

Three main mechanisms
- DNA methylation: Adding methyl groups to DNA usually lowers gene activity, especially when it happens at gene promoters. Enzymes that add methyl groups are called DNA methyltransferases; enzymes that remove them are demethylases.
- Histone modifications: DNA wraps around histone proteins. Adding or removing chemical groups (like methyl or acetyl groups) changes how tightly DNA is packaged, which can suppress or boost gene expression.
- Non-coding RNA (ncRNA): Small RNA molecules (like microRNAs) and long noncoding RNAs regulate gene expression and chromatin marks, influencing many cellular processes, including immune and neuron-related genes.

Epigenetic drugs
Scientists are exploring drugs that target epigenetic marks:
- HDAC inhibitors (HDACi) and other agents that affect histone acetylation
- DNA methylation inhibitors
- Inhibitors of enzymes that remove epigenetic marks
These drugs often affect many genes at once, so researchers weigh potential benefits against possible off-target effects.

Epigenetics in major neurodegenerative conditions

Motor neuron diseases
- ALS (amyotrophic lateral sclerosis): Motor neurons degenerate, causing muscle weakness. ALS shows overall reduced histone acetylation (hypoacetylation). HDAC inhibitors can restore acetylation, reactivate downregulated genes, and reduce neuron death in models. Some drugs that influence SMN2 (a gene related to spinal motor neurons) are explored in spinal muscular atrophy (SMA) and could inform ALS approaches.
- SMA: Caused by SMN1 mutations; SMN2 copies modulate disease severity. Epigenetic drugs aim to boost SMN2 expression (e.g., via HDAC inhibitors) to raise functional SMN protein levels. Results vary across models and human trials, but this remains an active research area.

Other motor-neuron related conditions (briefly)
- Myasthenia gravis (MG): An autoimmune disease at the neuromuscular junction. Epigenetic factors (DNA methylation, ncRNA, and miRNA) influence immune regulation and disease risk. miRNA patterns in the thymus and blood show potential as biomarkers and therapeutic targets.

Central nervous system neurodegenerative diseases
- Alzheimer’s disease (AD): Epigenetic changes include:
- ncRNA: BACE1 antisense RNA (BACE1-AS) stabilizes BACE1 mRNA, potentially increasing beta-amyloid production.
- miRNAs: Several miRNAs (e.g., miR-146a, miR-9) are altered in AD brains.
- DNA methylation: Global hypomethylation with gene-specific changes; some genes tied to learning, memory, and immune responses show abnormal methylation.
- Histone marks: Reduced acetylation at certain histone sites; HDAC inhibitors can improve memory and reduce pathology in animal models.
- Treatments focus on supporting epigenetic balance, including vitamins (folate/B vitamins) that affect methylation and compounds that influence histone acetylation.
- Huntington’s disease (HD): Caused by a DNA repeat (CAG) in the huntingtin gene. HD shows reduced histone acetylation (hypoacetylation) and increased histone methylation at specific genes, leading to tighter chromatin and lower gene activity. HDAC inhibitors in models can reverse some effects, and several HDAC inhibitors have been tested in HD models.
- Parkinson’s disease (PD): Changes in non-coding RNAs and DNA methylation have been observed, including altered miRNA levels that affect dopamine neurons. Alpha-synuclein can interfere with histone acetylation, linking protein aggregation to epigenetic changes. HDAC inhibitors and SIRT inhibitors have shown protective effects in models; some approaches aim to normalize epigenetic marks to support neuron survival.
- Multiple sclerosis (MS): An autoimmune demyelinating disease with epigenetic involvement. miRNA patterns differ in brain and blood; DNA methylation changes (including at immune-related genes) are observed. Histone acetylation patterns change in lesions and later stages, and some HDAC inhibitors show promise in animal studies.

Myasthenia gravis (MG) and other autoimmune interactions
- MG shows epigenetic contributions from DNA methylation and ncRNA regulation, particularly miRNAs that influence immune cell function and thymus activity. These patterns may help in diagnosis and treatment decisions in MG.

Treatments and what they mean for patients
- Epigenetic therapies aim to correct misregulated gene activity by altering DNA methylation or histone marks. They can improve neuron survival and function in models, but many drugs affect many genes, which can cause side effects.
- In SMA and other motor-neuron disorders, HDAC inhibitors and related drugs have shown some positive effects in animals and some early human studies, but results vary.
- In Alzheimer’s and other CNS diseases, epigenetic drugs have shown potential to improve memory and reduce pathological features in animal studies. Human trials are still limited, and long-term safety remains a key consideration.
- For MS, MG, and other autoimmune neuropathies, epigenetic findings point to potential biomarkers and new therapeutic targets, but clinical use is not yet standard practice.

Bottom line
Epigenetics helps explain how gene activity, not just DNA sequence, influences neurodegenerative diseases. By understanding DNA methylation, histone modifications, and non-coding RNAs, researchers seek new ways to diagnose, monitor, and treat these conditions. While promising, many epigenetic therapies are still in research, and careful study is needed to ensure they are safe and effective for people.